Komodo Health's Real-World Evidence Platform Powers 31 Research Studies at ISPOR 2025
核心洞察
Komodo Health (搜索)'s healthcare intelligence platform enabled 31 research studies presented at the 2025 ISPOR global conference, including three studies led by Komodo researchers and 27 collaborative studies with academic institutions and Life Sciences companies.
The research spans multiple therapeutic areas including oncology, cardiovascular disease, metabolic disorders, neurology, and rare diseases, demonstrating the platform's versatility in addressing critical evidence gaps.
The platform provides a multidimensional view of 330+ million patient journeys by linking de-identified claims data with specialty datasets, enabling researchers to generate evidence faster and more accurately.
Komodo Health (搜索) announced that its healthcare intelligence platform enabled 31 research studies being presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) global conference. The studies include three led by Komodo researchers and 27 collaborative studies with academic institutions, Life Sciences companies, and healthcare organizations.
"The volume and diversity of research powered by our healthcare insights underscore the growing demand for high-quality real-world data combined with advanced analytical capabilities," said Arif Nathoo, MD, CEO and Co-Founder, Komodo Health (搜索). "By connecting individual patient journeys to large-scale health outcomes, we're enabling researchers to uncover actionable insights that improve clinical practice, healthcare policy, and patient outcomes."
Diverse Therapeutic Applications
The ISPOR 2025 research presentations demonstrate the value of Komodo's real-world evidence across multiple therapeutic areas:
Oncology: Salix Pharmaceuticals, Analysis Group (搜索), and Bausch Health studied the economic burden of opioid-induced constipation (搜索) among patients with or without cancer (搜索).
Cardiovascular disease: Veradigm (搜索) examined the discordance between apolipoprotein B (搜索) and low-density lipoprotein cholesterol (搜索) levels in predicting incident hypertension (搜索) risk and how it correlates to differential hypertension development patterns between diabetic and non-diabetic populations.
Metabolic disorders: Novo Nordisk studied non-invasive diagnostic approaches and earlier interventions for metabolic dysfunction-associated steatohepatitis (搜索) (MASH).
Neurology: Jazz Pharmaceuticals analyzed healthcare resource utilization and costs among individuals with narcolepsy (搜索) or idiopathic hypersomnia (搜索) (IH) who are considered at higher risk for negative clinical outcomes associated with sodium due to underlying cardiovascular, cardiometabolic, or renal conditions.
Rare disease: Chiesi (搜索) analyzed medical claims data to better understand healthcare resource utilization patterns among Fabry disease (搜索) patients.
Methodological Advances
Three poster presentations by Komodo researchers showcase methodological advances including sequential target trial emulation to assess mortality impact of amyotrophic lateral sclerosis (搜索) treatments, benchmarking injectable medication duration through claims interval versus days supply analysis, and expanding longitudinal patient data through tokenized linkage technology.
Comprehensive Data Integration
Komodo provides a multidimensional view of 330+ million patient journeys by linking de-identified claims data with specialty datasets, including lab results, genomics, and demographic information through its platform to address fundamental challenges in health economics and outcomes research (HEOR). The platform enables researchers to link disparate datasets without the months typically spent on data cleaning and integration.
The option to enhance disease understanding at the patient level with lab, EHR, patient insurance, race and ethnicity, and mortality data enables teams to self-serve cohort feasibility and insights. This ability accelerates study planning timelines by weeks and generates more accurate estimates of treatment patterns, healthcare resource utilization, and costs.
"By closing critical data gaps and providing a patient-centric approach to HEOR, our powerful, all-in-one platform brings clean, connected, and compliant real-world data together," Nathoo added. "We eliminate the need for messy integrations, manual data wrangling, and coding cohorts from scratch, which enables HEOR teams to generate evidence faster. The inclusion of race, ethnicity, mortality, and other demographic insights at a near-census level also allows researchers to better model the clinical and financial impacts of new therapies across diverse populations, addressing the reality that disease burden is not borne equally across demographic groups."